USA - NASDAQ:RVMD - US76155X1000 - Common Stock
The current stock price of RVMD is 58.87 USD. In the past month the price increased by 26.52%. In the past year, price increased by 5.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063 US
CEO: Mark A. Goldsmith
Employees: 534
Phone: 14157663638
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 700 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
The current stock price of RVMD is 58.87 USD. The price increased by 1.47% in the last trading session.
RVMD does not pay a dividend.
RVMD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
RVMD stock is listed on the Nasdaq exchange.
The Revenue of REVOLUTION MEDICINES INC (RVMD) is expected to grow by 1308.5% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
REVOLUTION MEDICINES INC (RVMD) has a market capitalization of 11.00B USD. This makes RVMD a Large Cap stock.
ChartMill assigns a technical rating of 9 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 85.92% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to RVMD. No worries on liquidiy or solvency for RVMD as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -4.5. The EPS decreased by -23.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.46% | ||
| ROE | -26.49% | ||
| Debt/Equity | 0 |
24 analysts have analysed RVMD and the average price target is 77.27 USD. This implies a price increase of 31.25% is expected in the next year compared to the current price of 58.87.
For the next year, analysts expect an EPS growth of -53.26% and a revenue growth 1308.5% for RVMD